Skip to content
DataLookout
Menu

NCT07940244

A Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Timeframe: Up to Day 239
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Timeframe: Up to Day 239

Arms and interventions

BI 456906 formulation A (Reference) then BI 456906 formulation D1 (Test)Experimental

Subcutaneous administration of formulation A (Reference) then formulation D1 (Test)

BI 456906 formulation D1 (Test) then BI 456906 formulation A (Reference)Experimental

Subcutaneous administration of formulation D1 (Test) then formulation A (Reference)

Combination products: Survodutide formulation A, Survodutide formulation D1

Sites

1 site in 1 country

  • hVIVO MannheimMannheim, Germany